CD4 and neoplasm: Seventeen CD4+ TCR clonotypes were experimentally validated by reconstructing TCRs in healthy donor T cells and testing their reactivity to patient-specific neoantigens via coculture assays with antigen-presenting cells and autologous tumor material.